Could a simple shot replace IV treatments for severe bleeding disorder?
NCT ID NCT05500807
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether emicizumab (Hemlibra), a medicine given as a shot under the skin, can safely prevent bleeding in people with severe von Willebrand disease (VWD) or combined VWD/hemophilia A. About 40 participants of any age (including infants) will receive the drug and be monitored for bleeds and side effects. If successful, it could offer a more convenient alternative to current IV treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bleeding and Clotting Disorders Institute (BCDI)
RECRUITINGPeoria, Illinois, 61614, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Central Michigan University: Children's Hospital of Michigan
RECRUITINGMount Pleasant, Michigan, 48859, United States
Contact
Contact Email: •••••@•••••
-
Children's Mercy Hospital
RECRUITINGKansas City, Missouri, 64108, United States
Contact Email: •••••@•••••
Contact
-
Innovative Hematology, Inc. (IHI)
RECRUITINGIndianapolis, Indiana, 46260, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Penn State College of Medicine
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders
RECRUITINGTampa, Florida, 33607, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
Stanford University: Stanford Children's Health
RECRUITINGRedwood City, California, 94063, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD)
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UW Health Comprehensive Program for Bleeding Disorders
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
University of Miami - Miller School of Medicine
RECRUITINGCoral Gables, Florida, 33146, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Michigan Medical School
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Washington Center for Bleeding Disorders
RECRUITINGSeattle, Washington, 98101, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.